Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies the side effects and the best dose of
phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 when given together with rituximab in
treating patients with relapsed or refractory low-grade B-cell lymphoma. PI3K inhibitor
BKM120 may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
Some block the ability of cancer to grow and spread. Others find cancer cells and help kill
them or carry cancer-killing substances to them. Giving PI3K inhibitor BKM120 with rituximab
may be an effective treatment for B-cell lymphoma.